Medprin Regenerative Medical Technologies Co. Ltd. (301033) — Cash Flow-to-Debt Ratio

Latest as of December 2024: 1.17x

Medprin Regenerative Medical Technologies Co. Ltd. (301033) has a Cash Flow-to-Debt Ratio of 1.17x as of December 2024, meaning its operating cash flow of CN¥116.38 Million could theoretically repay 1% of its total liabilities (CN¥99.57 Million) in one year. See Medprin Regenerative Medical Technologie (301033) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

CF-to-Debt Ratio

1.17x
Operating CF / Total Liabilities

Operating Cash Flow

CN¥116.38 Million
CNY

Total Liabilities

CN¥99.57 Million
CNY

Data as of

Dec 2024
Most recent filing

Medprin Regenerative Medical Technologies Co. Ltd. Cash Flow-to-Debt Ratio (2019–2024)

Historical debt coverage capacity for Medprin Regenerative Medical Technologies Co. Ltd. across 6 annual periods. Also explore net asset growth rate of Medprin Regenerative Medical Technologie to track the company's year-over-year net asset growth rate.

Annual Cash Flow-to-Debt Ratio for Medprin Regenerative Medical Technologies Co. Ltd. (2019–2024)

Year-by-year debt coverage analysis for Medprin Regenerative Medical Technologies Co. Ltd.. For market capitalisation and broader financial context, see 301033 stock market capitalisation.

Year CF-to-Debt Ratio Operating CF (CNY) Total Liabilities YoY Change
2024 1.17x CN¥116.38 Million CN¥99.57 Million ▲ +64.0%
2023 0.71x CN¥107.69 Million CN¥151.11 Million ▲ +110.0%
2022 0.34x CN¥48.31 Million CN¥142.34 Million ▼ -12.8%
2021 0.39x CN¥66.51 Million CN¥170.92 Million ▲ +34.6%
2020 0.29x CN¥33.91 Million CN¥117.26 Million ▼ -65.5%
2019 0.84x CN¥31.27 Million CN¥37.27 Million
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.